Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;39(1):55-74.
doi: 10.1007/s10719-021-10024-w. Epub 2021 Nov 10.

Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease

Affiliations
Review

Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease

Inka Brockhausen et al. Glycoconj J. 2022 Feb.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that affects over 10 million aging people worldwide. This condition is characterized by the degeneration of dopaminergic neurons in the pars compacta region of the substantia nigra (SNpc) and by aggregation of proteins, commonly α-synuclein (SNCA). The formation of Lewy bodies that encapsulate aggregated proteins in lipid vesicles is a hallmark of PD. Glycosylation of proteins and neuroinflammation are involved in the pathogenesis. SNCA has many posttranslational modifications and interacts with components of membranes that affect aggregation. The large membrane lipid dolichol accumulates in the brain upon age and has a significant effect on membrane structure. The replacement of dopamine and dopaminergic neurons are at the forefront of therapeutic development. This review examines the role of membrane lipids, glycolipids, glycoproteins and dopamine in the aggregation of SNCA and development of PD. We discuss the SNCA-dopamine-neuromelanin-dolichol axis and the role of membranes in neuronal stem cells that could be a regenerative therapy for PD patients.

Keywords: Alpha-synuclein; Dolichol; Dopamine; Membrane lipids; Neuromelanin; Parkinson’s disease; Stem cells.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Gai, W.P., Yuan, H.X., Li, X.Q., Power, J.T., Blumbergs, P.C., Jensen, P.H.: In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol. 166(2), 324–333 (2000) - PubMed
    1. Stefanis, L.: α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. 2(2), a009399 (2012)
    1. Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., et al.: Targeting α-synuclein for treatment of Parkinson’s disease: mechanistic and therapeutic considerations. Lancet Neurol. 14(8), 855–866 (2015) - PubMed - PMC
    1. Videira, P.A.Q., Castro-Caldas, M.: Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. Front Neurosci. 12, 381 (2018). https://doi.org/10.3389/fnins.2018.00381 - DOI - PubMed - PMC
    1. Li, J., Uversky, V.N., Fink, A.L.: Conformational behavior of human alpha-synuclein is modulated by familial Parkinson’s disease point mutations A30P and A53T. Neurotoxicology 23(4–5), 553–567 (2002) - PubMed

Publication types

LinkOut - more resources